LBRX Lb Pharmaceuticals announces accelerated timing of topline results from the phase 3 Nova-2 trial of Lb-102 in schizophrenia
LBRX Lb Pharmaceuticals announces accelerated timing of topline results from the phase 3 Nova-2 trial of Lb-102 in schizophrenia